Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-1-21
pubmed:abstractText
Autoimmune diseases are marked by the presence of class-switched, high-affinity autoantibodies with pathogenic potential. Costimulation plays an important role in the activation of T cells and the development of T cell-dependent B cell responses. ICOS plays an indispensable role in the development of follicular helper T cells (T(FH) cells), which provide cognate help to germinal center (GC) B cells. We show that the levels of T(FH) cells and GC B cells in two different models of autoimmunity, the New Zealand Black/New Zealand White (NZB/NZW) F(1) mouse model of systemic lupus erythematosus and the collagen-induced arthritis model of rheumatoid arthritis, are dependent on the maintenance of the ICOS/B7RP-1 pathway. Treatment with an anti-B7RP-1 Ab ameliorates disease manifestations and leads to a decrease in T(FH) cells and GC B cells as well as an overall decrease in the frequency of ICOS(+) T cells. Coculture experiments of Ag-primed B cells with CXCR5(+) or CXCR5(-) T cells show that blocking B7RP-1 does not directly impact the production of IgG by B cells. These findings further support the role of ICOS in autoimmunity and suggest that the expansion of the T(FH) cell pool is an important mechanism by which ICOS regulates Ab production.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1550-6606
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
182
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1421-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19155489-Animals, pubmed-meshheading:19155489-Antibodies, Blocking, pubmed-meshheading:19155489-Antibodies, Monoclonal, pubmed-meshheading:19155489-Antigens, CD80, pubmed-meshheading:19155489-Antigens, Differentiation, T-Lymphocyte, pubmed-meshheading:19155489-Arthritis, Experimental, pubmed-meshheading:19155489-Autoantibodies, pubmed-meshheading:19155489-B-Lymphocytes, pubmed-meshheading:19155489-Cell Differentiation, pubmed-meshheading:19155489-Female, pubmed-meshheading:19155489-Germinal Center, pubmed-meshheading:19155489-Inducible T-Cell Co-Stimulator Ligand, pubmed-meshheading:19155489-Inducible T-Cell Co-Stimulator Protein, pubmed-meshheading:19155489-Lupus Erythematosus, Systemic, pubmed-meshheading:19155489-Lymphocyte Activation, pubmed-meshheading:19155489-Male, pubmed-meshheading:19155489-Mice, pubmed-meshheading:19155489-Mice, Inbred BALB C, pubmed-meshheading:19155489-Mice, Inbred DBA, pubmed-meshheading:19155489-Mice, Inbred NZB, pubmed-meshheading:19155489-Random Allocation, pubmed-meshheading:19155489-Signal Transduction, pubmed-meshheading:19155489-T-Lymphocytes, Helper-Inducer
pubmed:year
2009
pubmed:articleTitle
B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells.
pubmed:affiliation
Department of Inflammation, Amgen, Inc., Thousand Oaks, CA 91320, USA.
pubmed:publicationType
Journal Article